Theravance Biopharma
TBPH | NASDAQ
$17.03
$0.00 (0.00%)
At close: Sep 23, 2026, 4:00 PM ET
Theravance Biopharma Company Profile
Company profile explainedCompany Profile
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Rick E. Winningham | Chief Executive Officer & Director |
| Stuart Knight | Senior Vice President of IT&I and Chief Information Officer |
| Aine Miller | Senior Vice President of Development & Head of Ireland Office |
| Aziz Sawaf | Senior VP of Operations Strategy & CFO |
| Brett A. Grimaud | Senior Vice President, General Counsel & Secretary |
| Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial & Medical Affairs |
| Stacy L. Pryce | Senior Vice President & Chief Strategy Officer |
Theravance Biopharma
| Country | United States |
| IPO Date | May 16, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 90 |
| CEO | Rick E. Winningham |
Contact Details
901 Gateway Boulevard South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | TBPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583107 |
| CUSIP Number | G8807B106 |
| ISIN Number | KYG8807B1068 |
| SIC Code | 2834 |
Recent News
- 10 months ago / zacks.comIs the Options Market Predicting a Spike in Theravance Biopharma Stock?
- 10 months ago / zacks.comWhy Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
- 10 months ago / zacks.comWhy Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Add to Watchlist
Select watchlists to add or remove TBPH